CoChat

Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis

Kahn, Richard, Alperin, Peter, Eddy, David, Borch-Johnsen, Knut, Buse, John, Feigelman, Justin, Gregg, Edward, Holman, Rury R, Kirkman, M Sue, Stern, Michael, Tuomilehto, Jaakko, Wareham, Nick J · 2010 · The Lancet

The DOI matches its Crossref record; 52 of the 56 references it cites were found in a registry or an index.

Abstract

Background No clinical trials have assessed the effects or cost-effectiveness of sequential screening strategies to detect new cases of type 2 diabetes. We used a mathematical model to estimate the cost-effectiveness of several screening strategies. Methods We used person-specific data from a representative sample of the US population to create a simulated population of 325,000 people aged 30 years without diabetes. We used the Archimedes model to compare eight simulated screening strategies for type 2 diabetes with a no-screening control strategy. Strategies differed in terms of age at initiation and frequency of screening. Once diagnosed, diabetes treatment was simulated in a standard manner. We calculated the effects of each strategy on the incidence of type 2 diabetes, myocardial infarction, stroke, and microvascular complications in addition to quality of life, costs, and cost per quality-adjusted life-year (QALY). Findings Compared with no screening, all simulated screening strategies reduced the incidence of myocardial infarction (3-9 events prevented per 1000 people screened) and diabetes-related microvascular complications (3-9 events prevented per 1000 people), and increased the number of QALYs (93-194 undiscounted QALYs) added over 50 years. Most strategies prevented a significant number of simulated deaths (2-5 events per 1000 people). There was little or no effect of screening on incidence of stroke (0-1 event prevented per 1000 people). Five screening strategies…

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(09)62162-0

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 52 references

Cited by

See all 287

Metadata

Authors
Kahn, R., Alperin, P., Eddy, D., Borch-Johnsen, K., Buse, J., Feigelman, J., Gregg, E., Holman, R. R., Kirkman, M. S., Stern, M., Tuomilehto, J., & Wareham, N. J.
Affiliations
  • American Diabetes Association (US)
  • University of North Carolina at Chapel Hill (US)
  • Centers for Disease Control and Prevention (US)
  • University of Oxford (GB)
  • University of Helsinki (FI)
Venue
The Lancet
Publisher
Elsevier BV
Published
2010-04
Volume
375
Issue
9723
Pages
1365-1374
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2139265932
Cited by
287
References
56
Citations by year
2026: 10 · 2025: 8 · 2024: 11 · 2023: 19 · 2022: 15 · 2021: 20 · 2020: 11 · 2019: 7 · 2018: 12 · 2017: 15 · 2016: 23 · 2015: 23 · 2014: 13 · 2013: 26 · 2012: 31
FWCI
73.84
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Novo Nordisk
  • Pfizer
  • Bayer HealthCare
Topics
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
type 2 diabetes, diabetes screening, cost-effectiveness, age at screening initiation, screening frequency, quality-adjusted life years, myocardial infarction, stroke, microvascular complications, diabetes prevention
MeSH terms
Adult, Age Factors, Aged, Cardiovascular Diseases, Cost-Benefit Analysis, Diabetes Mellitus, Type 2, Humans, Hyperlipidemias, Hypertension, Mass Screening, Middle Aged, Models, Theoretical, Models, Statistical, Quality-Adjusted Life Years, Stroke

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. https://app.cochat.ai/papers/10.1016/s0140-6736(09)62162-0
The paper
Kahn, R., Alperin, P., Eddy, D., Borch-Johnsen, K., Buse, J., Feigelman, J., Gregg, E., Holman, R. R., Kirkman, M. S., Stern, M., Tuomilehto, J., & Wareham, N. J. (2010). Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. The Lancet. https://doi.org/10.1016/s0140-6736(09)62162-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.